menu
    • menu
    [{"orgOrder":0,"company":"Freya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FB-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Freya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Freya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Freya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"MVA-BN-WEV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"MVA-BN-WEV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bavarian Nordic \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Bavarian Nordic \/ US Department of Defense"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"SNIPR Biome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biome \/ Inapplicable"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Large Molecule","year":"2024","type":"Funding","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"SNIPR Biome \/ CARB-X","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biome \/ CARB-X"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"SNIPR Biome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biome \/ Inapplicable"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"SNIPR Biome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biome \/ Inapplicable"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"SNIPR Biome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biome \/ Inapplicable"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"SNIPR Biome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biome \/ Inapplicable"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"SNIPR Biome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biome \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"MVA-BN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bavarian Nordic \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Bavarian Nordic \/ CEPI"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bavarian Nordic

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed

                            Bavarian Nordic

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MVA-BN

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : CEPI

                            Deal Size : $6.5 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in Africa

                            Details : The partnership aims to advance the development of Bavarian Nordic’s mpox vaccine, MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic, a non-replicating vaccine, in children in Africa.

                            Product Name : MVA-BN

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 30, 2024

                            Lead Product(s) : MVA-BN

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : CEPI

                            Deal Size : $6.5 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SNIPR Biome

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : CARB-X

                            Deal Size : $5.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            SNIPR Biome Receives CARB-X Funding to Advance SNIPR001 in Haematological Cancers

                            Details : Funding supports SNIPR Biome’s CRISPR-medicine SNIPR001, undergoing early-stage trials for E. coli bloodstream infections in patients with hematological cancers.

                            Product Name : SNIPR001

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            April 22, 2024

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : CARB-X

                            Deal Size : $5.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Freya Biosciences

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed

                            Freya Biosciences

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FB-101

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Freya Biosciences Announces Positive Topline Clinical Trial Results for FB101 in Women with Asymptomatic Vagin...

                            Details : FB101, is an investigational vaginal microbial immunotherapeutic, which is investigated for the treatment of Women with Asymptomatic Vaginal Dysbiosis.

                            Product Name : FB-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 27, 2023

                            Lead Product(s) : FB-101

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MinervaX

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed

                            MinervaX

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GBS-NN/NN2,GBS/NN2

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : European and Developing Countries Clinical Trials Partnership

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MinervaX Announces Completion of Enrolment in Phase I Clinical Vaccine Trial as it Addresses the Global Burden...

                            Details : GBS-NN/NN2 is a novel innovative, adjuvanted protein Vaccine which are based on traditional capsular polysaccharide (CPS) conjugate technology and investigated for the treatment of Group B Streptococcus.

                            Product Name : GBS-NN/NN2

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            June 27, 2023

                            Lead Product(s) : GBS-NN/NN2,GBS/NN2

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : European and Developing Countries Clinical Trials Partnership

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SNIPR Biome

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SNIPR Biome Reports Positive Clinical Interim Results for Groundbreaking, First-in-Human, CRISPR-based Microbi...

                            Details : SNIPR001 is a novel, first-in-human, CRISPR-based microbial gene therapy, developed to specifically target and remove E. coli, including antibiotic-resistant strains, from the human gastrointestinal tract.

                            Product Name : SNIPR001

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            May 31, 2023

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bavarian Nordic

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed

                            Bavarian Nordic

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MVA-BN-WEV

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : US Department of Defense

                            Deal Size : $83.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Bavarian Nordic Enters Agreement Valued up to USD 83 Million with the U.S. Department of Defense to Further Ad...

                            Details : MVA-BN WEV, a prophylactic vaccine candidate, is a multi-valent vaccine candidate since it incorporates antigens from all three equine encephalitis viruses: western, eastern and Venezuelan.

                            Product Name : MVA-BN-WEV

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            December 23, 2022

                            Lead Product(s) : MVA-BN-WEV

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : US Department of Defense

                            Deal Size : $83.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            SNIPR Biome

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SNIPR Biome Further Strengthens CRISPR/Cas IP Portfolio With Patent Grant

                            Details : SNIPR’s CRISPR technology provides a highly selective way to target individual bacterial strains for killing which can be useful for the prevention and treatment of any indication where a specific bacterial strain is the underlying cause of a disease.

                            Product Name : SNIPR001

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            December 22, 2022

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            SNIPR Biome

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001

                            Details : The experimental CRISPR therapeutic, SNIPR001, is designed to selectively target and eradicate E. coli in the gut, thus preventing translocation of these bacteria to the bloodstream, in a high-risk population of hematological cancer patients at risk for ...

                            Product Name : SNIPR001

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            April 20, 2022

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            SNIPR Biome

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SNIPR Biome Launches A Non-Profit Patent Licensing Program To Enable The Field of CRISPR Editing in Prokaryote...

                            Details : SNIPR001, is the first orally dosed CRISPR-based therapeutic candidate and CRISPR-armed bacteriophage cocktail that targets antibiotic-resistant E. coli infections in hematological cancer patients.

                            Product Name : SNIPR001

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            March 10, 2022

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            SNIPR Biome

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SNIPR Biome Granted New US Patent Covering Lytic CRISPR Phage

                            Details : SNIPR001, a CRISPR-armed bacteriophage cocktail that targets the prevention of antibiotic-resistant E. coli infections in hematological cancer patients.

                            Product Name : SNIPR001

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            February 08, 2022

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth